Differences in Prevalence and Incidence of Electrocardiogram Abnormalities and Cardiovascular Autonomic Neuropathy Among Randomized Glucose-Lowering Treatments in Early Type 2 Diabetes: The Glycemia Reduction Approaches in Diabetes (GRADE) Cohort

What Was Tested

The paper reports a study of Insulin Glargine and Liraglutide, published as a randomized controlled trial.

To describe the prevalence and incidence of electrocardiogram (ECG) abnormalities and ECG-derived cardiovascular autonomic neuropathy (CAN) in the GRADE cohort of adults with type 2 diabetes (T2D) <10 years.

Who Took Part

According to the abstract, 4,769 participants were involved.

By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.

Resting ECGs were completed at the baseline, 2-year, and 4-year study visits and analyzed for minor and major abnormalities and CAN assessed with heart rate variability (HRV) in 4,769 participants.

Incidence of new major, minor, and any ECG abnormalities and CAN by treatment group was analyzed using logistic repeated-measures models at years 2 and 4 adjusted for baseline risk factors.

How the Study Was Run

The researchers set it up as a randomized study.

Random assignment meant chance, not the researchers, decided who got Insulin Glargine and who got the comparison, which limits bias.

Individuals with T2D taking metformin alone were randomly assigned to add insulin glargine, glimepiride, liraglutide, or sitagliptin.

What Was Measured

Topics PubMed links to this paper include Diabetes Mellitus, Type 2, Electrocardiography, Hypoglycemic Agents, Liraglutide, Metformin, Sulfonylurea Compounds and Prevalence.

What This Means in Plain Language

The paper is a randomized study of Insulin Glargine and Liraglutide in 4,769 participants.

With several hundred people or more, it is a fairly large study for this kind of research.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2025 (Diabetes care), a journal based in United States.

More context: the Insulin Glargine compound page and the Liraglutide compound page.